Live price temporarily unavailable.
Climb Bio (CLYM) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$20.9M | −$35.7M | −$45.1M | −$40.3M | −$82.0M | −$67.9M |
| Net income | −$20.7M | −$47.5M | −$45.2M | −$35.1M | −$73.9M | −$59.9M |
| EPS (diluted) | −$4.66 | −$2.83 | −$1.72 | −$1.30 | −$1.53 | −$0.88 |
| Balance sheet | ||||||
| Cash and equivalents | $20.5M | $46.9M | $43.6M | $93.1M | $87.2M | $35.7M |
| Total assets | $24.6M | $173.2M | $135.0M | $110.5M | $217.2M | $167.7M |
| Total liabilities | $3.06M | $6.04M | $6.28M | $2.87M | $5.31M | $7.27M |
| Shareholders' equity | −$25.0M | $167.2M | $128.7M | $107.6M | $211.9M | $160.5M |
| Cash flow | ||||||
| Operating cash flow | −$14.1M | −$36.1M | −$37.4M | −$20.6M | −$15.6M | −$54.4M |
| Capital expenditure | — | — | — | $0 | $0 | $186.0K |
| Free cash flow | — | — | — | −$20.6M | −$15.6M | −$54.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$11.7M | −$10.9M | −$23.0M | −$10.7M | −$14.9M | −$19.3M | −$15.2M | −$15.4M |
| Net income | −$8.89M | −$8.42M | −$20.8M | −$8.67M | −$12.9M | −$17.5M | −$13.7M | −$13.5M |
| EPS (diluted) | −$0.13 | $0.47 | −$0.31 | −$0.13 | −$0.19 | −$0.25 | −$0.20 | −$0.18 |
| Balance sheet | ||||||||
| Cash and equivalents | $146.2M | $87.2M | $29.0M | $22.7M | $25.8M | $35.7M | $8.36M | $44.1M |
| Total assets | $222.2M | $217.2M | $200.7M | $192.4M | $182.3M | $167.7M | $152.4M | $246.3M |
| Total liabilities | $3.42M | $5.31M | $7.36M | $6.62M | $5.30M | $7.27M | $4.29M | $6.75M |
| Shareholders' equity | $218.8M | $211.9M | $193.4M | $185.8M | $177.0M | $160.5M | $148.1M | $239.5M |
| Cash flow | ||||||||
| Operating cash flow | −$7.55M | −$5.52M | −$15.4M | −$11.1M | −$12.1M | −$15.6M | −$14.4M | −$10.5M |
| Capital expenditure | $0 | $0 | — | — | $109.0K | $0 | — | — |
| Free cash flow | −$7.55M | −$5.52M | — | — | −$12.2M | −$15.6M | — | — |
From Climb Bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Climb Bio in our feed yet.